This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

FLORIDA – Thousands of mosquitoes infected with the Wolbachia bacteria were released in an area of the Florida Keys this week, in hopes of a new approach to control the disease-carrying female Aedes aegypti mosquito, which transmits Zika virus, Dengue fever and Chikungunya.

According to the Florida Keys Mosquito Control District, 20,000 male Aedes aegypti mosquitoes were released on Stock Island Tuesday for a field trial that will last 12 weeks. The mosquitoes, which do not bite, have been manually infected with a naturally occurring bacteria called Wolbachia.

Wolbachia is found in the cells of many insects but not mosquitoes, so the bacterium is manually injected into the mosquitoes in a lab in advance of the trial.

As explained in a presentation by the Florida Keys Mosquito Control District, when these infected male Aedes aegypti mosquitoes mate with female Aedes aegypti mosquitoes, the eggs she produces won’t hatch, thus they can’t reproduce. The result, they hope, will be a reduced or eliminated population of female Aedes aegypti mosquitoes and the viruses they spread, including Zika virus.

Zika is a great concern to pregnant women and those hoping to become pregnant because it can have devastating consequences for babies born to mothers who were infected while pregnant. One in 10 Zika-infected mothers had babies with related birth defects in the United States last year, according to the US Centers for Disease Control and Prevention.

“A successful trial with the Wolbachia-infected mosquitoes could mean the availability of a new tool in the fight against the Aedes aegypti mosquito for not only our District, but for Mosquito Control Districts around the country,” said Andrea Leal, executive director for the Florida Keys Mosquito Control District.

These Wolbachia-infected mosquitoes will be released twice a week at 20 different spots in the designated area for the trial. While the male mosquitoes don’t bite, “increases of mosquito activity will be most noticeable immediately following the releases,” the mosquito control office warned.

The mosquito control officials in The Keys are working with Kentucky based MosquitoMate for this trial. The company conducted a similar trial in Clovis, California, in August 2016.

Outside of the United States, the first Wolbachia-infected mosquitoes were released into the suburbs of Cairns, Australia, in 2011 and quickly spread into the wild, replacing the disease-carrying population with the new, disease-free one, and replicating quickly into subsequent generations.

According to the research group Eliminate Dengue, testing so far shows the helpful bacteria remain. Additional field trials are underway in Indonesia, Vietnam, Colombia and Brazil.

But the officials in Florida haven’t put all of their eggs in one basket. They are also trying to move forward with a trial of genetically modified mosquitoes from British company Oxitec. OX513A is a male Aedes aegypti mosquito that is genetically engineered to pass along a lethal gene to their female counterparts that makes the offspring die.

The gene creates a protein that interferes with cell activity, killing the mosquito before it can reach adulthood. According to Oxitec, field trials in Brazil, Panama and the Cayman Islands resulted in a 90% reduction of Aedes aegypti mosquitoes over six months.

The US Food and Drug Administration approved the Oxitec trial in the Keys last summer but it has not moved forward because of community backlash and logistics. The Florida Keys Mosquito District said it is awaiting FDA approval on a proposed change in location for the trial.

To date, 5,238 cases of the Zika virus have been reported in the continental US and Hawaii, according to the CDC. Less than 300 reported cases have been locally transmitted. Florida and Texas are the only states in the continental US to report local transmission from infected mosquitoes, as most people are infected while traveling to areas where the virus is circulating.